🧬 Silencing Risk: Lepodisiran vs Lp(a)
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New hope for high Lp(a)! 💉 Lepodisiran, a long-acting siRNA, slashed Lp(a) by 94% with just 2 shots/year. 🔬 RNA precision meets cardiac prevention. 📉 Silent killer, silenced. #CardioTwitter #RNAtherapy #LipoproteinA
info_outline
💨 Breathing Battles: Navigating COPD Phenotypes
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🌬️🚶♂️ COPD comes in many forms! From chronic bronchitis 🪫 to emphysema 💨, frequent exacerbators 🚨, asthma-COPD overlap 🌪️, and eosinophilic type 🧫. Tailoring treatment to phenotype is key! #COPD #PrecisionMedicine #RespiratoryCare
info_outline
💊 TANDEM Triumph: Dual Power for LDL Cholesterol Reduction!
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 TANDEM Trial: Combining Obicetrapib & Ezetimibe for a powerful LDL reduction! 💊 ✅ -48.6% vs placebo, -27.9% vs Ezetimibe, -16.8% vs Obicetrapib 💪 Safe, effective, and oral! #Cardiology #LipidManagement #ASCVD
info_outline
Fungal Pharmacists, Fatty Liver, Future Frontiers 🧬🩸🍄
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
A gut fungus 🍄 (Fusarium foetens) secretes FF-C1 🧪, a metabolite that inhibits CerS6 and lowers ceramides 🩸—shielding mice from MASH 🛡️. Fungi aren’t just freeloaders—they may be our next therapeutic allies! 💊🧠 #Microbiome #LiverHealth #FungalTherapy #Science
info_outline
💪 Powerful Cholesterol Control: Obicetrapib in the Spotlight 🌟
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 Obicetrapib: A Breakthrough in LDL Lowering! 📉 Reduced LDL by 29.9% in high-risk patients (p<0.001) 💡 Promising adjunct to lipid-lowering therapy! #Cardiology #LipidManagement #HeartHealth 💓
info_outline
Fat Chance! 🔬🧬 Middle-Age Spread Starts at the Cellular Level
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Here’s a tweet with emojis based on the article: 🧬 Middle-age spread decoded! 🕰️ Visceral fat grows in midlife not from bigger cells—but new ones! 🎯 CP-A cells fire up fat formation via LIFR–STAT3 🔥 💊 Targeting them may halt metabolic disease before it starts. #Aging #Obesity #CellBiology #Metabolism 🧫 Would you like a version with a more humorous tone or one tailored for clinicians?
info_outline
🔍📊🛡️ Detect, Decode, Defend: A New Era in Coronary Risk Prediction
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New era in heart disease prediction! 🧬 + 🧪 + 🤖 = Meta-prediction model that beats PCE & QRISK3 📈 Detects hidden CAD risk in young, women & “low-risk” groups 🎯 Precision prevention just got personal. 🫀 Published in Nature Medicine #CardioTwitter #AI #Genomics #CAD
info_outline
Dr RR Baliga's Philosophical Discourses: Epicurus (Greece, 341–270 BCE) – Founder of Epicureanism
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Epicurus (341–270 BC) was an ancient Greek philosopher who founded Epicureanism, emphasizing the pursuit of a tranquil, happy life through ataraxia (freedom from fear) and aponia (absence of pain). His teachings combined atomism, ethics, and naturalistic theology, advocating simple living, friendship, and the rejection of superstition.
info_outline
Calcium Wars: Orbital Atherectomy vs. Balloon Angioplasty — The ECLIPSE Verdict ⚔️🧠💔
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨ECLIPSE Trial Results🚨 Orbital atherectomy 🌀 vs. balloon angioplasty 🎈 before stenting in severe coronary calcification 💔 🎯 No added benefit with atherectomy 🧠 Balloon-first + imaging = smart strategy 📊 Lancet 2025 | #CardioTwitter #InterventionalCardiology #ECLIPSETrial
info_outline
Genes 🧬, Journeys 🌍, and Hidden Hazards ⚡: Unlocking Health with Exposomics
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
“Your DNA 🧬 is just half the story — your exposome 🌍 writes the rest! From air 🌫️ to food 🍎 to stress 😰, exposomics unlocks the hidden drivers of health 🔍💥. Predict. Prevent. Prosper. 🚀 #Exposomics #PrecisionMedicine”
info_outlineRecent randomized trials, including EARLY TAVR, AVATAR, RECOVERY, and EVOLVED, suggest benefits of early aortic valve replacement (AVR) in asymptomatic severe aortic stenosis (AS).
Early AVR reduces stroke, heart failure hospitalizations, and cardiovascular events, with a trend toward improved survival.
The data support shifting from clinical surveillance to early intervention?